JERSEY CITY, N.J., Jan. 11, 2018 /PRNewswire/ -- SCYNEXIS, Inc.
(NASDAQ:SCYX), a biotechnology company delivering innovative
anti-infective therapies for difficult-to-treat and often
life-threatening infections, today announced that the Company will
participate in a panel entitled "Novel Ways to Treat and/or Address
Infections" at the Cantor Antibiotics Summit at the Omni Berkshire
Hotel, New York, on Wednesday, January 17, 2018 at 12:15 p.m. ET.
About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ:SCYX) is a
biotechnology company committed to positively impacting the lives
of patients suffering from difficult-to-treat and often
life-threatening infections by delivering innovative anti-infective
therapies. The SCYNEXIS team has extensive experience in the life
sciences industry, discovering and developing more than 30
innovative medicines over a broad range of therapeutic areas. The
Company's lead product candidate, SCY-078, is a novel IV/oral
antifungal agent in Phase 2 clinical and pre-clinical development
for the treatment of several serious and life-threatening invasive
fungal infections caused by Candida and Aspergillus species. For
more information, visit www.scynexis.com.
CONTACT:
Investor
Relations
Susan Kim
Argot Partners
Tel: 212-203-4433
susan@argotpartners.com
Media Relations
Cammy Duong
MacDougall Biomedical Communications
Tel: 781-591-3443
cduong@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/scynexis-to-participate-in-the-cantor-antibiotics-summit-300581688.html
SOURCE SCYNEXIS, Inc.